Results 11 to 20 of about 133,537 (299)
Signal Transduction and Targeted Therapy, 2022 Metabolic enzymes have an indispensable role in metabolic reprogramming, and their aberrant expression or activity has been associated with chemosensitivity. Hence, targeting metabolic enzymes remains an attractive approach for treating tumors.
Jin-Fei Lin +14 more
semanticscholar +1 more source
Advancement of science, 2023 Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer (CRC); however, frequent drug resistance limits its therapeutic efficacy in patients.
K. Zeng +7 more
semanticscholar +1 more source
PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer
Nature Communications, 2023 Despite being an effective treatment for hepatocellular carcinoma (HCC), resistance to oxaliplatin presents a major obstacle. Here, the authors identify PRMT3-induced methylation of IGF2BP1 resulting in HEG1 stabilisation as a mechanism of oxaliplatin ...
Yunxing Shi +16 more
semanticscholar +1 more source
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]
, 2015 Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim +6 more
core +11 more sources
Cancer Cell International, 2023 Background Oxaliplatin-based chemotherapy is the first-line treatment for colorectal cancer (CRC). Long noncoding RNAs (lncRNAs) have been implicated in chemotherapy sensitivity. This study aimed to identify lncRNAs related to oxaliplatin sensitivity and
Qing-nan Zhou +5 more
doaj +1 more source
Signal Transduction and Targeted Therapy, 2022 Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an estimated 50% of patients will eventually stop responding to treatment due to acquired resistance.
Yimin Li +14 more
semanticscholar +1 more source
Molecular Therapy: Oncolytics, 2021 Although oxaliplatin is an effective chemotherapeutic drug commonly used for colorectal cancer (CRC) treatment, drug resistance usually occurs during the long-term use of it.
Wei Sun +4 more
doaj +1 more source
Acta Biochimica et Biophysica Sinica, 2023 Currently, platinum-containing regimens are the most commonly used regimens for advanced gastric cancer patients, and chemotherapy resistance is one of the main reasons for treatment failure.
Li Suyao +14 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Oxaliplatin-based chemotherapy is a standard treatment approach for colorectal cancer (CRC). However, oxaliplatin-induced peripheral neurotoxicity (OIPN) is a severe dose-limiting clinical problem that might lead to treatment interruption.
Fang Cheng +9 more
semanticscholar +1 more source
Therapeutic Advances in Medical Oncology, 2021 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dosage-limited oxaliplatin-related toxicity. To date, there are no successful interventions for CIPN prevention or treatment.
Barliz Waissengrin +6 more
doaj +1 more source